Therapy of autoimmune diseases: Clinical trials and new biologics

Current Opinion in Immunology

Volumn 14, Issue 6, 2002, Pages 812-815

  Nepom, Gerald T ^a  

^a BENAROYA RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID DERIVATIVE; ALEMTUZUMAB; BASILIXIMAB; CD2 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD52 ANTIGEN; DACLIZUMAB; EPRATUZUMAB; ETANERCEPT; GLUTIRAMIR ACETATE; IMMUNOMODULATING AGENT; INFLIXIMAB; INTERLEUKIN 2 RECEPTOR; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; NATALIZUMAB; OKT 3; ONERCEPT; RITUXIMAB; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 1; GLATIRAMER; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; PEPTIDE;

AUTOIMMUNE DISEASE; CLINICAL TRIAL; CROHN DISEASE; DRUG EFFICACY; HUMAN; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; MULTIPLE SCLEROSIS; PROTEIN PROTEIN INTERACTION; PSORIASIS; REVIEW; ULCERATIVE COLITIS; B LYMPHOCYTE; DRUG EFFECT; T LYMPHOCYTE;

ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; MULTIPLE SCLEROSIS; PEPTIDES; T-LYMPHOCYTES;

EID: 0036888572     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(02)00397-7     Document Type: Review

References (42)

1. Chaudhari U., Romano P., Mulchahy L.D., Dooley L.T., Baker D.G., Gottlieb A.B. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 357:2001;1842-1847.
2. Sieper J., Braun J. New treatment options in ankylosing spondylitis: a role for anti-TNFα therapy. Ann Rheum Dis. 60:2002;58-61.
3. Mease P.J. Cytokine blockers in psoriatic arthritis. Ann Rheum Dis. 60:2002;37-40.
4. Furst D.E., Keystone E.C., Breedveld F.C., Kalden J.R., Smolen J.S., Antoni C.E., Burmester G.R., Crofford L.J., Kavanaugh A. Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001). Ann Rheum Dis. 60:2001;iii2-iii5. An expert panel of the American College of Rheumatology summarizes recommendations for anti-TNF therapies in rheumatoid arthritis.
5. Keating G.M., Perry C.M. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis. Bio Drugs. 16:2002;111-148.
6. Skurkovich S., Boiko A., Beliaeva I., Buglak A., Alekseeva T., Smirnova N., Kulakova O., Tchechonin V., Gurova O., Deomina T., et al. Randomized study of antibodies to IFN-γ and TNF-α in secondary progressive multiple sclerosis. Mult Scler. 7:2001;277-284.
7. Trentham D.E., Dynesius-Trentham R.A., Orav E.J., Combitchi D., Lorenzo C., Sewell K.L., Hafler D.A., Weiner H.L. Effects of oral administration of type II collagen on rheumatoid arthritis. Science. 261:1993;1727-1730.
8. Barnett M.L., Kremer J.M., St Clair E.W., Clegg D.O., Furst D., Weisman M., Fletcher M.J., Chasan-Taber S., Finger E., Morales A., et al. Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 41:1998;290-297.
9. Keller R.J., Eisenbarth G.S., Jackson R.A. Insulin prophylaxis in individuals at high risk of type I diabetes. Lancet. 341:1993;927-928.
10. Diabetes Prevention Trial-Type 1 Diabetes Study Group . Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med. 346:2002;1685-1691. A multicentre randomised trial of 139 individuals, selected from 84,228 screened for high risk of autoimmune diabetes. Parenteral prophylactic insulin had no effect on incidence or rate of progression to diabetes.
11. Bielekova B., Goodwin B., Richert N., Cortese I., Kondo T., Afshar G., Gran B., Eaton J., Antel J., Frank J.A., et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand. Nat Med. 6:2000;1167-1175.
12. Kappos L., Comi G.C., Panitch H., Oger J., Antel J., Conlon P., Steinman L. The Altered Peptide Ligand in Relapsing MS Study Group: induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. Nat Med. 6:2000;1176-1182.
13. Choy E.H., Scott D.L., Kingsley G.H., Thomas S., Murphy A.G., Staines N., Panayi G.S. Control of rheumatoid arthritis by oral tolerance. Arthritis Rheum. 44:2001;1993-1997.
14. Bielekova B., Martin R. Antigen-specific immunomodulation via altered peptide ligands. J Mol Med. 79:2001;552-565. A thorough summary and discussion of the complex issues surrounding the potential for altered peptide antigen-based therapy in multiple sclerosis.
15. Husby S., Mestecky J., Moldoveanu Z., Holland S., Elson C.O. Oral tolerance in humans. T cell but not B cell tolerance after antigen feeding. J Immunol. 152:1994;4663-4670.
16. Reich K., Garbe C., Blaschke V., Maurer C., Middel P., Westphal G., Lippert U., Neumann C. Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation. J Invest Dermatol. 116:2001;319-329.
17. Friedrich M., Docke W.D., Klein A., Philipp S., Volk H.D., Sterry W., Asadullah K. Immunomodulation by interleukin-10 therapy decreases the incidence of relapse and prolongs the relapse-free interval in Psoriasis. J Invest Dermatol. 118:2002;672-677.
18. Egan C.A., Brown M., White J.D., Yancey K.B. Treatment of epidermolysis bullosa acquisita with the humanized anti-Tac mAb daclizumab. Clin Immunol. 101:2001;146-151.
19. Haufs M.G., Haneke E. Epidermolysis bullosa acquisita treated with basiliximab, an interleukin-2 receptor antibody. Acta Derm Venereol. 81:2001;72.
20. Gavin M.A., Clarke S.R., Negrou E., Gallegos A., Rudensky A. Homeostasis and anergy of CD4(+)CD25(+) suppressor T cells in vivo. Nat Immunol. 3:2002;33-41.
21. Willis F., Marsh J.C., Bevan D.H., Killick S.B., Lucas G., Griffiths R., Ouwehand W., Hale G., Waldmann H., Gordon-Smith E.C. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol. 114:2001;891-898.
22. Brett S., Baxter G., Cooper H., Johnston J.M., Tite J., Rapson N. Repopulation of blood lymphocyte sub-populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH-1H. Immunology. 88:1996;13-19.
23. Isaacs J.D., Watts R.A., Hazleman B.L., Hale G., Keogan M.T., Cobbold S.P., Waldmann H. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet. 340:1992;748-752.
24. Schulze-Koops H., Davis L.S., Haverty T.P., Wacholtz M.C., Lipsky P.E. Reduction of Th1 cell activity in the peripheral circulation of patients with rheumatoid arthritis after treatment with a non-depleting humanized monoclonal antibody to CD4. J Rheumatol. 25:1998;2065-2076.
25. Herold K.C., Hagopian W., Auger J.A., Poumian-Ruiz E., Taylor L., Donaldson D., Gitelman S.E., Harlan D.M., Xu D., Zivin R.A., et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med. 346:2002;1692-1698. Demonstration that loss of insulin secretory function in newly diagnosed diabetics can be arrested by potent short term immunotherapy.
26. Ellis C.N., Krueger G.G. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med. 345:2001;248-255.
27. Krueger G.G. Selective targeting of T cell subsets: focus on alefacept-a remittive therapy for psoriasis. Expert Opin Biol Ther. 2:2002;431-441.
28. da Silva A.J., Brickelmaier M., Majeau G.R., Li Z., Su L., Hsu Y.M., Hochman P.S. Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells. J Immunol. 168:2002;4462-4471.
29. Papp K., Bissonnette R., Krueger J.G., Carey W., Gratton D., Gulliver W.P., Lui H., Lynde C.W., Magee A., Minier D., et al. The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol. 45:2001;665-674.
30. Tutrone W.D., Kagen M.H., Barbagallo J., Weinberg J.M. Biologic therapy for psoriasis: a brief history, II. Cutis. 68:2001;367-372.
31. Gordon F.H., Hamilton M.I., Donoghue S., Greenlees C., Palmer T., Rowley-Jones D., Dhillon A.P., Amlot P.L., Pounder R.E. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to α-4 integrin. Aliment Pharmacol Ther. 16:2002;699-705.
32. Gordon F.H., Lai C.W., Hamilton M.I., Allison M.C., Srivastava E.D., Fouweather M.G., Donoghue S., Greenlees C., Subhani J., et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology. 121:2001;268-274.
33. Tubridy N., Behan P.O., Capildeo R., Chaudhuri A., Forbes R., Hawkins C.P., Hughes R.A., Palace J., Sharrack B., Swingler R., et al. The effect of anti-α4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology. 53:1999;466-472.
34. Bhushan M., Bleiker T.O., Ballsdon A.E., Allen M.H., Sopwith M., Robinson M.K., Clarke C., Weller R.P., Graham-Brown R.A., Keefe M., et al. Anti-E-selectin is ineffective in the treatment of psoriasis: a randomized trial. Br J Dermatol. 146:2002;824-831.
35. Perrotta S., Locatelli F., La Manna A., Cennamo L., De Stefano P., Nobili B. Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. Br J Haematol. 116:2002;465-467.
36. Quartier P., Brethon B., Philippet P., Landman-Parker J., Le Deist F., Fischer A. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet. 358:2001;1511-1513.
37. Zaja F., Iacona I., Masolini P., Russo D., Sperotto A., Prosdocimo S., Patriarca F., de Vita S., Regazzi M., Baccarani M., et al. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica. 87:2002;189-195.
38. Fusco C., Andreone V., Coppola G., Luongo V., Guerini F., Pace E., Florio C., Pirozzi G., Lanzillo R., Ferrante P., et al. HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis. Neurology. 57:2001;1976-1979.
39. Khan O.A., Tselis A.C., Kamholz J.A., Garbern J.Y., Lewis R.A., Lisak R.P. A prospective, open-label treatment trial to compare the effect of IFNβ-1a (Avonex), IFNβ-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis: results after 18 months of therapy. Mult Scler. 7:2001;349-353.
40. Khan O.A., Tselis A.C., Kamholz J.A., Garbern J.Y., Lewis R.A., Lisak R.P. A prospective, open-label treatment trial to compare the effect of IFNβ-1a (Avonex), IFNβ-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis. Eur J Neurol. 8:2001;503-504.
41. Flechter S., Vardi J., Pollak L., Rabey J.M. Comparison of glatiramer acetate (Copaxone(R)) and interferon beta-1b (Betaferon(R)) in multiple sclerosis patients: an open-label 2-year follow-up. J Neurol Sci. 197:2002;51-55.
42. Calabresi P.A. Considerations in the treatment of relapsing-remitting multiple sclerosis. Neurology. 58:2002;S10-S22.